Degarelix
ATC Code
L02BX02
Degarelix
Definition
A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.
Also known as ASP 3550, ASP-3550, ASP3550, DEGARELIX, FE 200486, FE-200486, FE200486, Firmagon — per NCIT
Also identified as
- ATC L02BX02 per RXNORM
- NCIT NCIT:C48385 per NCIT
- SCTID 441758000 per RXNORM
- SCTID 441864003 per RXNORM
- UNII SX0XJI3A11 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Prostate cancer | may treat | MEDRT · Public domain (U.S. Government work) |